Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug4054 | Sphenopalatine Ganglion Block with Placebo (Isotone NaCl) Wiki | 1.00 |
drug4053 | Sphenopalatine Ganglion Block with Local Anesthetic Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of this study is to evaluate the effect of the ganglion sphenopalatine block (SPG block) on persistent headache following acute COVID-19 infection.
Description: Pain intensity will be measured as worst experienced pain after the patient has been standing for 30 seconds or the worst experienced pain while attempting to stand if the rating has to be interrupted.
Measure: Hyperactivity in the sphenopalatine ganglion assessed by pain intensity (0-100mm on a visual analogue scale, VAS) of the postdural headache in standing position in the group Ropivacine-Lidocaine and "sham". Time: 30 minutes after blockDescription: Pain intensity measured as worst experienced pain after the patient has been standing for 30 seconds or the worst experienced pain while attempting to stand if the rating has to be interrupted.
Measure: Number of patients with pain rating below 30mm in standing position (0-100mm on a visual analogue scale, VAS) Time: 30 minutes and 1 week after blockDescription: The worst experienced pain reported during the week following the block as registered by the patient.
Measure: Worst experienced pain in standing position (0-10 on a numercial rating scale, NRS) Time: During study period until completion of 1 week follow upDescription: The average pain intensity reported during the week following the block as registered by the patient.
Measure: Average pain intensity (0-10 on a numercial rating scale, NRS) Time: During study period until completion of 1 week follow upDescription: If the patient at the 1 week follow up still needs further treatment a "rescue SPG-block" defined as a new SPG-block with "open label" analgetics will be offered.
Measure: Number of patients needing "rescue GSP-block" Time: At 1 week follow upDescription: Pain intensity will be measured as worst experienced pain after the patient has been standing for 30 seconds or the worst experienced pain while attempting to stand if the rating has to be interrupted.
Measure: Hyperactivity in the sphenopalatine ganglion assessed by pain intensity (0-100mm on a visual analogue scale, VAS) of the postdural headache in standing position in all 3 groups. Time: 30 minutes after blockDescription: The use of analgesics during the week following the block as registered by the patient and the patient file.
Measure: Analgesics used daily in the week following the SPG-block Time: During study period until completion of 1 week follow upAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports